Cite
Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study.
MLA
Meng, Rui Ping, et al. “Effectiveness and Safety of Vedolizumab and Infliximab in Biologic‐naïve Patients with Moderate‐to‐severe Ulcerative Colitis: A Multicenter, Retrospective Cohort Study.” Journal of Digestive Diseases, vol. 25, no. 4, Apr. 2024, pp. 230–37. EBSCOhost, https://doi.org/10.1111/1751-2980.13270.
APA
Meng, R. P., Huang, B. B., Wei, Y. L., Lyu, L., Yang, H., Liu, C., Zhou, H. L., Liao, X. P., Zhou, J. Y., & Xie, X. (2024). Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study. Journal of Digestive Diseases, 25(4), 230–237. https://doi.org/10.1111/1751-2980.13270
Chicago
Meng, Rui Ping, Bao Bao Huang, Yan Ling Wei, Lin Lyu, Huan Yang, Cheng Liu, Hong Li Zhou, Xi Ping Liao, Jian Yun Zhou, and Xia Xie. 2024. “Effectiveness and Safety of Vedolizumab and Infliximab in Biologic‐naïve Patients with Moderate‐to‐severe Ulcerative Colitis: A Multicenter, Retrospective Cohort Study.” Journal of Digestive Diseases 25 (4): 230–37. doi:10.1111/1751-2980.13270.